Research Progress On A Third-generation Mineralocorticoid Receptor Antagonist In Heart Failure-finerenone

Mineralocorticoid receptor antagonists have been demonstrated to effectively reduce hospitalization rate and mortality in patients with cardiac failure.However,steroid mineralocorticoid receptor antagonists have not been sufficiently utilized in clinical settings,and it is largely due to the risk of inducing severe adverse events,including hyperkalemia and deterioration of renal function.Therefore,new selective non-steroid mineralocorticoid receptor antagonists are clinically developed.Among the new antagonists,finerenone shows favorable curative effect and less adverse effect.Current research progress concerning finerenone is overviewed in the paper.